<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H7DDA9E433968478893B8393FB80FBC6C" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 3631 IH: Vaccines in Trial and Liability Act of 2025</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-05-29</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 3631</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250529">May 29, 2025</action-date><action-desc><sponsor name-id="G000590">Mr. Green of Tennessee</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To criminalize fraudulent statements made with respect to clinical vaccine trials.</official-title></form><legis-body id="H5D4F9E7DD06C421DB27D5649CB5A5580" style="OLC"> 
<section id="H03F93AAA47AF4C0C9C070E7F203947BD" section-type="section-one"><enum>1.</enum><header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Vaccines in Trial and Liability Act of 2025</short-title></quote> or the <quote><short-title>VITAL Act of 2025</short-title></quote>.</text></section> 
<section id="HFD5541E16B304423BBD06E032B2D05B3"><enum>2.</enum><header>Medical research company or sponsor</header> 
<subsection id="HA1268058D5234780A3F3D41E36049001"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline"><external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/18/47">Chapter 47</external-xref> of title 18, United States Code, is amended by adding at the end the following:</text> <quoted-block style="USC" id="H089AF25918F74F2FBDC1296058132922" display-inline="no-display-inline"> <section id="H3888107BFFE94606BF8B72A33B6C2DD3"><enum>1041.</enum><header>Clinical vaccine trial fraud</header><text display-inline="no-display-inline">Whoever, being a medical research company or sponsor, makes a fraudulent statement to, or conceals from, any department or agency of the United States, any material data collected from a clinical vaccine trial, shall be fined under this title, imprisoned not more than 5 years, or both.</text></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="H6CB73CC7BBBD465D9E36690D7AAF5AB3"><enum>(b)</enum><header>Clerical amendment</header><text>The table of sections for <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/18/47">chapter 47</external-xref> of title 18, United States Code, is amended by adding at the end the following:</text> <quoted-block style="USC" id="H0705E5F52C174A43845A97D558AF1DF6" display-inline="no-display-inline"> <toc regeneration="no-regeneration"> <toc-entry level="section">1041. Clinical vaccine trial fraud.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section> <section id="H0470AD21684447DF99D0A0FB87CECB03"><enum>3.</enum><header>Scope of authorization</header><text display-inline="no-display-inline">Section 564(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-3">21 U.S.C. 360bbb–3(c)</external-xref>) is amended—</text> 
<paragraph id="H760FEFAFD50E43E283101B8BD26F9B61">
                <enum>(1)</enum>
 <text>in paragraph (4), by striking <quote>and</quote>;</text> </paragraph> <paragraph id="H1E5BCA2CBD074C018DD5C2770DDED740"><enum>(2)</enum><text>by redesignating paragraph (5) as paragraph (6); and</text></paragraph> 
<paragraph id="H1BC2BDDC0DA846928C09BFF7A2910DAA"><enum>(3)</enum><text>by inserting after paragraph (4) the following:</text> <quoted-block style="OLC" id="H415CD6ED6163400686D69C0BF3E6FB61" display-inline="no-display-inline"> <paragraph id="HE79E7D46A3B34DD78F7215F76958B995"><enum>(5)</enum><text display-inline="yes-display-inline">the authorization is based on a certification by a medical research company or sponsor that no fraudulent material statements were made, and no material information was concealed, with respect to the circumstances described under subsection (b)(1) or the criteria under this subsection; and</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section> 
<section id="H28CE5861DA28490D81224D586C97046C"><enum>4.</enum><header>Revision and revocation</header><text display-inline="no-display-inline">Section 564(g)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-3">21 U.S.C. 360bbb–3(g)(2)</external-xref>) is amended—</text> <paragraph id="H4102B5DBE6804B608B378F2514CF4C89"><enum>(1)</enum><text>in subparagraph (B), by striking <quote>or</quote> at the end;</text></paragraph> 
<paragraph id="H8002BD560D4540B7BB776E394DE1D916"><enum>(2)</enum><text>by redesignating subparagraph (C) as subparagraph (D); and</text></paragraph> <paragraph id="HCFD32A95DE0A4C31BAB3DC3C7DC24E4C"><enum>(3)</enum><text>by inserting after subparagraph (B) the following:</text> 
<quoted-block style="OLC" id="H93823764A41047FD83BBD54E1E8087C6" display-inline="no-display-inline"> 
<subparagraph id="H76C0F67E5C7140018F2C6865DE2324DF"><enum>(C)</enum><text display-inline="yes-display-inline">the Secretary determines that fraudulent material statements were made, or material information was concealed, with respect to the circumstances described under subsection (b)(1) or the criteria under subsection (c); or</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section> <section id="HF07C6BEFA6144FF1B23A1C77BB95B3CF"><enum>5.</enum><header>Exception to limitation on liability</header><text display-inline="no-display-inline">Section 2(b)(1) of the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (21 U.S.C. 360bbb–0a note) is amended—</text> 
<paragraph id="HC333380989594CA5821738DA7C6BEF91"><enum>(1)</enum><text>in subparagraph (A), by inserting <quote>, unless a fraudulent material statement was made, or material information was concealed, with respect to data collected from a clinical trial of the investigational drug</quote> before the semicolon; and</text></paragraph> <paragraph id="H660625A9081741EC9D76D71745361D45"><enum>(2)</enum><text>in subparagraph (B), by inserting <quote>, including a fraudulent material statement made, or material information concealed, with respect to data collected from a clinical trial of the investigational drug</quote> before the period.</text></paragraph></section> 
<section id="HA1FB5965D2C24888BADB96BDEEF68AFC"><enum>6.</enum><header>Exception to targeted liability protections for pandemic and epidemic products</header><text display-inline="no-display-inline">Section 319F–3 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-6d">42 U.S.C. 247d–6d</external-xref>) is amended—</text> <paragraph id="H7D0CD006B7064834A51898EE98173EC9"><enum>(1)</enum><text>in subsection (c)—</text> 
<subparagraph id="HE3DE98F642534F6888853ECEDF90E8B5"><enum>(A)</enum><text>in paragraph (1)(A)—</text> <clause id="H24482627D5A34B2D9283E5EFB94E0965"><enum>(i)</enum><text>by redesignating clauses (i), (ii), and (iii) as subclauses (I), (II), and (III), respectively;</text></clause> 
<clause id="H41444E9620404E7C9558C3FE59F14B83"><enum>(ii)</enum><text>by moving subclauses (I), (II), and (III), as redesignated, 2 ems to the right;</text></clause> <clause id="H282344693B8B4558B84893EA4093C9FB"><enum>(iii)</enum><text>by striking the period at the end of subclause (III) and inserting <quote>; and</quote>, as redesignated;</text></clause> 
<clause id="H29D749FEDF3944FC96E25E2A76F8DCFB"><enum>(iv)</enum><text>by striking <quote>subsection (d), denote</quote> and inserting the following:</text> <quoted-block style="OLC" id="H7277DE93B89741CA89555356CF4AAFF7" display-inline="yes-display-inline"><text display-inline="yes-display-inline">subsection (d)—</text> 
<clause id="H235789B52DBA40BAB3913FC73FA41326"><enum>(i)</enum><text display-inline="yes-display-inline">denote</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block></clause> <clause id="HA9C6700A009D4D57A01E7882B9DEC736"><enum>(v)</enum><text>by adding at the end the following:</text> 
<quoted-block style="OLC" id="H10A0B4970397424D8182241770114471" display-inline="no-display-inline"> 
<clause id="H120F1FFFD8794322A89D1E43DF8604BF"><enum>(ii) </enum><text display-inline="yes-display-inline">includes—</text> <subclause id="H56B2661E0EBE4B148F61E162AD64DF1E"><enum>(I)</enum><text>making a fraudulent material statement with respect to data collected from a clinical trial; or</text></subclause> 
<subclause id="H66F48561E42B4BE8BB3736E23E89C405"><enum>(II)</enum><text display-inline="yes-display-inline">concealing material information with respect to data collected from a clinical trial.</text></subclause></clause><after-quoted-block>; and</after-quoted-block></quoted-block></clause></subparagraph> <subparagraph id="H8ABA73F92DFE49359E41903402300D67"><enum>(B)</enum><text>in paragraph (5)(A)—</text> 
<clause id="HBFF7DDFBC3424CFFB97C6E14B467E0E4"><enum>(i)</enum><text>in the matter preceding clause (i), by striking <quote>subsection (d) if—</quote> and inserting <quote>subsection (d)—</quote>;</text></clause> <clause id="HB82D02543E0343BBA2D0E408017113B7"><enum>(ii)</enum><text>in clause (i)—</text> 
<subclause id="H1D6C95FC016B464085E1F260D35E9F82"><enum>(I)</enum><text>by inserting <quote>if</quote> before <quote>neither</quote>; and</text></subclause> <subclause id="H7DEB4FD1B9634CF5AB02AEBF1E64896A"><enum>(II)</enum><text>by striking <quote>or</quote> at the end;</text></subclause></clause> 
<clause id="H9CC7FD8608A04E55909B9E4A0FCEDC93"><enum>(iii)</enum><text>in clause (ii)—</text> <subclause id="H6D3289D4A40E4560BE23243BFE84F1A7"><enum>(I)</enum><text>by inserting <quote>if</quote> before <quote>such an enforcement</quote>; and</text></subclause> 
<subclause id="HABC01869DF294FE3A53433125904FF2C"><enum>(II)</enum><text>by striking the period at the end and inserting <quote>; and</quote>; and</text></subclause></clause> <clause id="H34A0955416434AC881008E58F9D7717F"><enum>(iv)</enum><text>by adding at the end the following:</text> 
<quoted-block style="OLC" id="H62DA4E1EE08749D1BF524B10963BC234" display-inline="no-display-inline"> 
<clause id="HB3B0D271554140B59235DF5F25B87EE7"><enum>(iii)</enum><text display-inline="yes-display-inline">unless the Secretary determines, after notice and opportunity for a hearing, that a fraudulent material statement was made, or material information was concealed, by a covered person with respect to data collected from a clinical trial of a covered countermeasure.</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block></clause></subparagraph></paragraph> <paragraph id="H735E5C7B47C6470FBB255D98E04CD124"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (e)—</text> 
<subparagraph id="H422FFA83DB08410793D12E294303FD21"><enum>(A)</enum><text display-inline="yes-display-inline">by striking paragraph (7); and</text></subparagraph> <subparagraph id="HA2C5FFAA0E2F4D11B5F55520207C6B02"><enum>(B)</enum><text>by adding at the end the following:</text> 
<quoted-block style="OLC" id="H37FFDCF11F7949FCA627FBA2ADBEEAD9" display-inline="no-display-inline"> 
<paragraph id="H2EE0B142170046949FD68B9891F2DB43"><enum>(11)</enum><header>Award of damages</header><text display-inline="yes-display-inline">Notwithstanding any other provision of law, the amount of an award of damages made to a plaintiff may not be reduced because of any other award for damages the plaintiff may receive as a result of such claim. </text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></section> <section id="H1F7430439FBB4AE79C7F24BED29B32F9"><enum>7.</enum><header>National Vaccine Injury Compensation Program</header><text display-inline="no-display-inline">Section 2122 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300aa-22">42 U.S.C. 300aa–22</external-xref>) is amended by adding at the end the following:</text> 
<quoted-block style="OLC" id="HFA30FCCB7B754D869A5A8E180EB41D43" display-inline="no-display-inline"> 
<subsection id="H845023C5973143C8BD9302E1261C28F1"><enum>(f)</enum><header>Liability</header> 
<paragraph id="HD3F6531850C747F9BD36F538842B60AF"><enum>(1)</enum><header>Fraudulent material statement</header><text>No civil action against a vaccine manufacturer or vaccine sponsor shall be barred under this part if the Secretary determines, after notice and opportunity for a hearing, that a fraudulent material statement was made, or material information was concealed, by a vaccine manufacturer with respect to data collected from a clinical trial of a vaccine.</text></paragraph> <paragraph id="H4AAC80E29BE14D65B60BB47354890C0C"><enum>(2)</enum><header>Award of damages</header> <subparagraph id="H4F160E8A902643289F2C5F6B8A843B6E"><enum>(A)</enum><header>In general</header><text>Notwithstanding any other provision of law, an plaintiff bringing a claim pursuant to paragraph (1) may—</text> 
<clause id="HA72FF209ADFD48F199C51645628D1C7B"><enum>(i)</enum><text>seek compensation under the program established under this part; and</text></clause> <clause id="HF91F1A3BF1B54659900241A7914281B2" commented="no"><enum>(ii)</enum><text>concurrently bring an action with respect to such claim in any appropriate United States district court.</text></clause></subparagraph> 
<subparagraph id="HE0370FB8928E4815B7CCB99944350CD7"><enum>(B)</enum><header>Award of damages</header><text>Notwithstanding any other provision of law, the amount of an award of damages made to a plaintiff for a claim pursuant to paragraph (1) may not be reduced on the basis of any other damages the plaintiff may receive as a result of such claim.</text></subparagraph></paragraph> <paragraph id="HE6849D75320D46E1B097B7E4AE9C54B4" commented="no"><enum>(3)</enum><header>Applicability with respect to COVID–19 vaccine</header><text display-inline="yes-display-inline">Notwithstanding any other provision of law, a civil action against a vaccine manufacturer pursuant to paragraph (1) with respect to a vaccine related to COVID–19 may be made at any time.</text></paragraph> 
<paragraph id="H919938D9DEDB48AE9286CA1B72DCD93A"><enum>(4)</enum><header>COVID–19 definition</header><text display-inline="yes-display-inline">In this section, the term <term>COVID–19</term> means the coronavirus disease caused by the severe acute respiratory syndrome coronavirus 2 or the SARS–CoV–2. This term also relates to any and all variations of that virus of which there is no termination date for this term.</text></paragraph></subsection><after-quoted-block/></quoted-block></section> <section id="HBA12F85268D845E493C60F67280012C6"><enum>8.</enum><header>Liability hearing</header> <subsection id="H925A3058E27743EC8962B77C296F1683"><enum>(a)</enum><header>Fraudulent material or statements</header><text display-inline="yes-display-inline">In the case that the Secretary of Health and Human Services determines that a vaccine manufacturer or vaccine sponsor has made fraudulent material or statements or concealed material information with respect to a situation described in this Act, or an amendment made by this Act, the Secretary shall and provide such manufacturer or sponsor 30 days to refute a determination made in a hearing described in subsection (b).</text></subsection> 
<subsection id="HB072EF5D6D904342AA8E6502086CF743" commented="no">
                <enum>(b)</enum>
                <header>Hearing</header>
                <paragraph id="H57C19098AF1E4950A06B27EA933C5066" commented="no">
                    <enum>(1)</enum>
                    <header>In general</header>
 <text>The Secretary shall determine a date, time, and format for a hearing under this subsection, including a requirement that the vaccine manufacturer or vaccine sponsor provide any requested document to the Secretary not more than five days before the hearing.</text>
                </paragraph>
                <paragraph id="H9B40AE3BFEC041C4B2708D41FE891CB8" commented="no">
                    <enum>(2)</enum>
                    <header>Format</header>
 <text>The format of a hearing under paragraph (1) shall be determined by the Secretary.</text>
                </paragraph>
                <paragraph id="H34A8CD067DA64AD393D7B0E1244FB5E2" commented="no">
                    <enum>(3)</enum>
                    <header>Publication</header>
 <text display-inline="yes-display-inline">Any written or verbal testimony submitted by the vaccine manufacturer or vaccine sponsor at the hearing under paragraph (1) shall be published on the internet website of the Secretary of Health and Human Services.</text>
                </paragraph>
            </subsection> 
<subsection id="HA37EF12BEC244989974BAAB8ADB45C69"><enum>(c)</enum><header>Does not provide information</header><text>In the case that the vaccine manufacturer or vaccine sponsor does not respond to the Secretary in accordance with this section, an initial determination of fraud shall be maintained and shall have the full force and effect of this Act.</text></subsection></section> </legis-body></bill>

